Mischa Vreeburg

GlycoMScan B.V. was founded in 2018 by dr. Monique van Scherpenzeel who switched her career from academia into a service company. She has experience in mass spectrometry and developed analytical methods for clinical diagnostics, with an expertise on protein glycosylation through studying patients with Congenital Disorders of Glycosylation. As postdoctoral fellow at the ETH in Zürich a nucleotide sugar analysis method was developed, based on their method to study central carbon metabolism. We serve national and international pharma and biotech companies with pharmacokinetics and analyses to characterize novel drug candidates, e.g. antibody-drug conjugates. As Eurostar we were involved in development of well-defined cell culture media to drive protein glycosylation, and developed the GLYSEC platform to analyze cell-surface glycosylation. Both are of high need in the field of immune-oncology to assist in finding new drug targets, as well as to improve drug potency and specificity. I am impressed by the scientific quality of the Swiss scientists and therefore I love to work with them. We already collaborate for years with EPFL in Lausanne, Asterivir and Orpha Labs. It is our pleasure to grow our network in Switzerland to further strengthen our company.